Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria~* Males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control~* Participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks~* C-peptide ≥1.0 ng/mL~* Body mass index ≤45.0 kg/m\^2~* Serum creatinine level \<1.50 mg/dL for men or \<1.40 mg/dL for women.~Key Exclusion Criteria~* Aspartate aminotransferase and/or alanine aminotransferase level \>3.0 times the upper limit of normal~* Serum total bilirubin level \>2 mg/dL~* Creatinine kinase level \>3 times upper limit of normal~* Symptoms of severely uncontrolled diabetes~* Serum creatinine level ≥1.50 mg/dL for men or ≥1.40 mg/dL for women~* Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Metformin (Type: PLACEBO_COMPARATOR): Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 2.5 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 5 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 10 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).